Medicinal active agents are based on the universal concept of target recognition. Their history is characterized by a limited number of revolutionary advances. The Paul Ehrlich ‘lock and key’ ...
MDRNA, Inc. (Nasdaq: MRNA) announced today positive in vivo efficacy data using a novel combination of a meroduplex siRNA and MDRNA’s proprietary lipid-based delivery platform, the DiLA 2 Platform.
Recent studies are revealing more about how the protein complex called RISC--RNA-induced silencing complex--works. RISC is at the heart of the gene-silencing technique called RNA interference, which ...
The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports. In its 15 years of existence, the fortunes of the RNAi therapeutics field ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results